Skip to main content
Last Updated
Case Status
In the Matter of Illumina, Incorporated, a corporation, and Pacific Biosciences of California, Incorporated, a corporation.
FTC Matter/File Number
Docket Number

Case Summary

The Federal Trade Commission authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California, alleging in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. On Jan. 2, 2020, the parties abandoned the transaction.